CymaBay Therapeutics to Announce Third Quarter 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
CymaBay Therapeutics to Announce Third Quarter 2014 Financial Results on Wednesday, November 12, 2014

NEWARK, CA --(Marketwired - October 31, 2014) - CymaBay Therapeutics, Inc. ( NASDAQ : CBAY ), today announced that it will host a conference call and live audio webcast on Wednesday, November 12 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the Company's financial results for the quarter ended September 30, 2014 and to provide a general business update.

Conference Call Details

To access the live conference call, please dial (877) 407-8913 from the U.S. and Canada, or (201) 689-8201 internationally and refer to conference ID 13593925.

To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events . A replay of the webcast will be available on the Company's website for 14 days following the live event.

About CymaBay

CymaBay Therapeutics, Inc. is focused on developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate, the company's lead product candidate, has shown two therapeutic actions in a single drug in Phase 2a gout studies. In gout patients, arhalofenate is intended to prevent painful attacks in joints while at the same time promoting excretion of serum uric acid (sUA) by the kidney, thereby addressing both the signs and symptoms of gout and the hyperuricemia that is the root cause of the disease. CymaBay is currently investigating arhalofenate in a 12-week Phase 2b clinical trial in patients with gout. The Company's second product candidate, MBX-8025 is a potent, selective, orally active PPAR-δ agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile that may be useful in the treatment of a variety of rare and orphan diseases currently under evaluation.

For additional information about CymaBay visit www.cymabay.com .

Contact: Sujal Shah  CymaBay Therapeutics, Inc.   (510) 293-8800   investors@cymabay.com or Adam Cutler  The Trout Group, LLC (646) 378-2936 CymaBay@troutgroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 157

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
HashKey and Base Aim to Bridge Asia With Liquidity

Updated Category News Views 79

A blockchain partnership can sound like confetti until the plumbing matters. This one at least points at a real commercial choke point: Asian-originated tokenized assets need deeper pools of global onchain capital, while global networks need credible asset supply and institutional access. HashKey Group's HSK Chain and Coinbase-built Base say they intend to tackle both...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 91

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading
Charter’s $1.5 Billion Tender Tests Debt Discipline

Updated Category News Views 227

Debt cleanup arrives with a hard ceiling Eight far-dated bond issues just got a very specific invitation from Charter Communications: hand them over for cash, but do not expect the company to write a blank check. Charter set final pricing on November 17 for tender offers covering up to $1.5 billion in aggregate consideration, excluding accrued interest and deal expenses....

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 257

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Azazie Tests Bridal Demand With Two East Coast Pop-Ups

Updated Category News Views 127

Wedding dresses are a miserable product to buy sight unseen, no matter how pretty the product photos look. That basic fact is why Azazie’s two East Coast pop-ups on November 21 and 22 deserve a closer look. This is not some grand retail rollout, and nobody should pretend a pair of short events rewrites the bridal market. But it is a practical test of where a...

Continue Reading
Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 25

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 159

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Markel Elevates War Risk Expertise in London Market

Updated Category News Views 42

A Specialty Desk Gets Its Own Weather Vane War and political violence underwriting is not a corner of insurance where a fancy title change can be shrugged off. The ground shifts under the policyholder, the broker and the carrier without much warning, and a bad call can sit on a book for years. Markel Insurance has named Chloe Gordge Director of War and Political Violence...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 182

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights from Key Shareholder Meetings: Tech and Industry Leaders

Updated Category News Views 229

Shareholder Meetings on the Horizon As we move into a new reporting season, the excitement surrounding the upcoming shareholder meetings is palpable. The recent financial results indicate a strong finish to the last quarter, with many companies showcasing impressive growth despite emerging macro challenges. The period after Q4 reporting sees a shift in focus toward the...

Continue Reading
Worldline Welcomes Pierre-Antoine Vacheron as CEO

Updated Category News Views 708

Worldline Welcomes Pierre-Antoine Vacheron as CEO Worldline, a leader in digital payments, has recently announced the appointment of Pierre-Antoine Vacheron as its new Chief Executive Officer. This strategic move, effective from March 1, signals a fresh start for the company as it continues to evolve within the rapidly changing payments industry. A Seasoned Professional...

Continue Reading
Autolus Therapeutics Set to Reveal Q2 2025 Financial Insights

Updated Category News Views 219

Autolus Therapeutics to Release Financial Results Soon Autolus Therapeutics plc (NASDAQ: AUTL), a pioneering biopharmaceutical company, is gearing up to share its financial results for the second quarter of 2025. This announcement is set for shortly before the opening of U.S. markets. As a company focusing on next-generation programmed T cell therapies, the anticipation...

Continue Reading
Brightworks Dentistry Unites Practices Under One Brand

Updated Category News Views 28

New Brand Strategy in Atlanta's Dental Scene In an era where large dental chains seem to gobble up neighborhood practices like some corporate Pac-Man, Dr. Patrice Robbins takes a refreshing turn. Her brainchild, Brightworks Dentistry, is roping in all its Atlanta bases under one banner to keep that local warmth alive. By grouping Dunwoody, Buckhead, and Downtown Atlanta...

Continue Reading
AutoNation's Analyst Coverage Sparks Interest in Key Stocks

Updated Category News Views 48

Recent Insights from Analysts on AutoNation Wall Street analysts have recently published their latest evaluations of several well-known companies, presenting a blend of ratings and insights. In this article, we’ll explore the most recent coverage initiated by leading analysts, focusing specifically on AutoNation, Inc. and other notable companies. Understanding the...

Continue Reading